Electra Therapeutics targets $977.6 million valuation in US IPO

Electra Therapeutics is pursuing an initial public offering in the United States, targeting a valuation of $977.6 million. The company aims to enter the US public market to secure capital and establish its financial position. This strategic move reflects the firm's current valuation goals as it prepares for the IPO process. The filing indicates a significant financial milestone for Electra Therapeutics as it seeks to attract investors through this upcoming listing on the US exchange.